{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:37:17Z","timestamp":1780670237130,"version":"3.54.1"},"reference-count":40,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2023,7,26]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Since its initial identification in 1956, respiratory syncytial virus (RSV) has been the second most common cause of mortality in infants &lt;6 months of age and a major cause of morbidity and mortality associated with lower respiratory tract infection (LRTI)\n in older adults (ages &gt;60 years) worldwide. Of particular interest to the allergist\/immunologist is a growing body of evidence that suggests an association between LRTI caused by RSV in infants with later-life development of asthma, wheezing, or impaired lung function in adults. Efforts\n to develop a RSV vaccine have been thwarted for &gt;70 years by the occurrence of enhanced respiratory disease (ERD), an adverse RSV vaccine reaction, in the 1960s, in which more-severe illness occurred on natural infection after vaccination of infants who were RSV naive and with a formalin-inactivated\n RSV vaccine. Recent advances in knowledge of the structural biology of the RSV surface fusion glycoprotein, however, have revolutionized RSV vaccine development for preventive interventions and have offered, at last, the hope of an effective and safe vaccine for the prevention of RSV disease.\n  <jats:bold>Objective:<\/jats:bold> The purpose of this report was to examine the current evidence that supports the epidemiology, disease manifestations, molecular biology, treatments, and new vaccine development of RSV vaccines.  <jats:bold>Results:<\/jats:bold> The host-immune response to RSV infection\n is carried out by two distinct but overlapping universes of mucosal and systemic immune systems in which a balanced set of B- and T-cell responses are involved in protective immunity that includes the mucosal immune system in which immunoglobulin A (IgA) prevails and the systemic immune system\n in which IgG neutralizing antibody predominates. The key to developing an effective vaccine is now thought to be linked to the availability of a stabilized prefusion F protein in the immunizing vaccine, which can perform a dual function of a balanced mucosal and\/or systemic immune response\n as well as an effective antibody specifically directed to critical epitopes on the requisite prefusion F protein.  <jats:bold>Conclusion:<\/jats:bold> The unfortunate manifestation of RSV ERD that occurred in the 1960s has led to a better understanding of the structural biology of the RSV surface\n fusion glycoprotein and has provided a basis for the development of more effective and safer RSV vaccines and monoclonal antibody preparations for immunoprophylaxis of the dread effects of RSV disease. There are now a large number of clinical trials in progress that are evaluating these products,\n which include recombinant vector, subunit, particle-based, live-attenuated, chimeric, and nucleic acid vaccines; and monoclonal antibodies. This article gives an overview of the many aspects of RSV disease and development of virus (RSV) vaccines of particular interest to the allergist\/immunologist.<\/jats:p>","DOI":"10.2500\/aap.2023.44.230030","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T01:05:25Z","timestamp":1685149525000},"page":"220-228","source":"Crossref","is-referenced-by-count":8,"title":["The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist\/immunologist"],"prefix":"10.2500","volume":"44","author":[{"given":"Lawrence D.","family":"Frenkel","sequence":"first","affiliation":[{"name":"From the Department of Biomedical Sciences, University of Illinois College of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunanda","family":"Gaur","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Bellanti","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cll.2004.05.008","article-title":"Major factors affecting the emergence and re-emergence of infectious diseases","volume":"24","author":"Church","year":"2004","journal-title":"Clin Lab Med"},{"key":"B2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1353\/bhm.2002.0022","article-title":"Updating the accounts: global mortality of the 1918\u20131920 \u201cSpanish\u201d influenza pandemic","volume":"76","author":"Johnson","year":"2002","journal-title":"Bull Hist Med"},{"key":"B3","article-title":"World Disasters Report 2022"},{"key":"B4","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3181\/00379727-92-22538","article-title":"Recovery of cytopathogenic agent from chimpanzees with coryza","volume":"92","author":"Morris","year":"1956","journal-title":"Proc Soc Exp Biol Med"},{"key":"B5","first-page":"281","article-title":"Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization","volume":"66","author":"Chanock","year":"1957","journal-title":"Am J Hyg"},{"key":"B6","article-title":"Respiratory Syncytial Virus Infection","volume-title":"StatPearls [Internet]","author":"Jain","year":"2023"},{"key":"B7","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","article-title":"Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape","volume":"23","author":"Mazur","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B8","volume-title":"Respiratory Syncytial Virus Infection","author":"Jain","year":"2023"},{"key":"B9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0300985814520639","article-title":"The relationship between respiratory syncytial virus and asthma","volume":"52","author":"Knudson","year":"2015","journal-title":"Vet Pathol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1586\/eri.11.92","article-title":"Evidence for a causal relationship between respiratory syncytial virus infection and asthma","volume":"9","author":"Wu","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/infdis\/162.6.1283","article-title":"Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children","volume":"162","author":"Hall","year":"1990","journal-title":"J Infect Dis"},{"key":"B12","first-page":"3","article-title":"Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jalm\/jfac058","article-title":"Summarizing study characteristics and diagnostic performance of commercially available tests for respiratory syncytial virus: a scoping literature review in the COVID-19 era","volume":"8","author":"Bernstein","year":"2023","journal-title":"J Appl Lab Med"},{"key":"B14","doi-asserted-by":"crossref","first-page":"938372","DOI":"10.3389\/fmicb.2022.938372","article-title":"Resurgence of respiratory syncytial virus infection during COVID-19 pandemic among children in Shanghai, China","volume":"13","author":"Jia","year":"2022","journal-title":"Front Microbiol"},{"key":"B15","article-title":"Increased respiratory virus activity, especially among children, early in the 2022\u20132023 Fall and Winter","year":"2022"},{"key":"B16","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJMc2216153","article-title":"Viral lineages in the 2022 RSV surge in the United States","volume":"388","author":"Adams","year":"2023","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CMR.12.2.298","article-title":"Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment","volume":"12","author":"Domachowske","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"B18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1542\/peds.48.5.715","article-title":"Biologic significance of the secretory IgA immunoglobulins","volume":"48","author":"Bellanti","year":"1971","journal-title":"Pediatrics"},{"key":"B19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1741-7015-11-153","article-title":"Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis","volume":"11","author":"Tricco","year":"2013","journal-title":"BMC Med"},{"key":"B20","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1016\/j.vaccine.2017.07.093","article-title":"Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus","volume":"35","author":"Suzuki","year":"2017","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJM196903202801202","article-title":"Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccines","volume":"280","author":"Bellanti","year":"1969","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2003.09.032","article-title":"Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine","volume":"22","author":"Bellanti","year":"2004","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1016\/j.vaccine.2018.08.056","article-title":"Humoral and cellular immunity to RSV in infants, children and adults","volume":"36","author":"Green","year":"2018","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"crossref","first-page":"S584","DOI":"10.1093\/infdis\/jiaa063","article-title":"Immunological and inflammatory biomarkers of susceptibility and severity in adult respiratory syncytial virus infections","volume":"222","author":"Wiseman","year":"2020","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2500\/aap.2022.43.220045","article-title":"Salivary and serum IgA and IgG responses to SARS-CoV-2-spike protein following SARS-CoV-2 infection and after immunization with COVID-19 vaccines","volume":"43","author":"Li","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"B26","doi-asserted-by":"crossref","first-page":"e0271622","DOI":"10.1128\/spectrum.02716-22","article-title":"SARS-CoV-2-neutralizing humoral IgA response occurs earlier but is modest and diminishes faster than IgG response","volume":"10","author":"Takamatsu","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/infdis\/jiaa483","article-title":"Antibody responses to respiratory syncytial virus: a cross-sectional serosurveillance study in the Dutch population focusing on infants younger than 2 years","volume":"224","author":"Berbers","year":"2021","journal-title":"J Infect Dis"},{"key":"B28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1442-200X.1995.tb03356.x","article-title":"Different kinetics of antibody responses between IgA and IgG classes in nasopharyngeal secretion in infants and children during primary respiratory syncytial virus infection","volume":"37","author":"Tsutsumi","year":"1995","journal-title":"Acta Paediatr Jpn"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.201412-2256OC","article-title":"Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus","volume":"191","author":"Habibi","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B30","doi-asserted-by":"crossref","first-page":"eabj7843","DOI":"10.1126\/scitranslmed.abj7843","article-title":"Fatal enhanced respiratory syncytial virus disease in toddlers","volume":"13","author":"Polack","year":"2021","journal-title":"Sci Transl Med"},{"key":"B31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jama.1967.03130250057008","article-title":"Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines","volume":"202","author":"Fulginiti","year":"1967","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1203\/PDR.0b013e3180686ce0","article-title":"Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple","volume":"62","author":"Polack","year":"2007","journal-title":"Pediatr Res"},{"key":"B33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJMp2216358","article-title":"The journey to RSV vaccines - heralding an era of structure-based design","volume":"388","author":"Graham","year":"2023","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/vaccines11020382","article-title":"The quest for a respiratory syncytial virus vaccine for older adults: thinking beyond the F protein","volume":"11","author":"Jenkins","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B35","doi-asserted-by":"crossref","first-page":"34108","DOI":"10.1038\/srep34108","article-title":"Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus","volume":"6","author":"Killikelly","year":"2016","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"crossref","first-page":"e230023","DOI":"10.1001\/jamanetworkopen.2023.0023","article-title":"Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis","volume":"6","author":"Sun","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B38","doi-asserted-by":"crossref","first-page":"e20182308","DOI":"10.1542\/peds.2018-2308","article-title":"Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial","volume":"143","author":"Alansari","year":"2019","journal-title":"Pediatrics"},{"key":"B39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"B40","volume-title":"Immunology IV: Clinical Applications in Health and Disease","author":"Bellanti","year":"2012"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2023\/00000044\/00000004\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T04:33:56Z","timestamp":1690346036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2023.44.230030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7,26]]}},"alternative-id":["1088-5412(20230726)44:4L.220;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2023.44.230030","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}